Cost Factors in CARE Act Formulas

HEHS-95-256R: Published: Sep 15, 1995. Publicly Released: Sep 15, 1995.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

Pursuant to a congressional request, GAO reviewed the effects of proposed acquired immune deficiency syndrome Title I and II funding on eligible metropolitan areas (EMA) and states. GAO noted that: (1) the proposed funding formula, with no cost factor, would increase Title I funding for 30 EMA, decrease funding for 10 EMA, and remain the same for 9 EMA; (2) after 5 years, Title I funding would increase for 32 EMA, decrease for 10 EMA, and remain the same for 7 EMA; (3) Title II funding with no cost factor, would increase during the first year for 15 states, decrease for 13 states, and remain the same for 26 states; (4) some states' Title II funding would remain unaffected because they received minimum grants, reached the funding floor, or were exempt from losing additional funds; and (5) after 5 years, Title II funding would increase for 19 states, decrease for 17 states, and remain the same for 18 states.

Apr 26, 2017

Apr 17, 2017

Apr 14, 2017

Apr 10, 2017

Mar 31, 2017

Mar 2, 2017

Feb 27, 2017

Feb 15, 2017

Feb 13, 2017

Feb 8, 2017

Looking for more? Browse all our products here